Exit Readiness Signals Framework

Is the growth we’re investing in today going to help us or quietly hurt us during diligence?

This framework is designed for healthcare, pharmacy, and health-tech companies operating in growth mode while keeping a future transaction (sale, recap, spin‑out, etc) in view. It helps leadership teams pressure‑test growth decisions through a buyer’s lens before those decisions create drag, confusion, or discounted valuation later.

HOW BUYERS EVALUATE GROWTH

In diligence, buyers aren't asking, "Did you grow?"

They’re asking:
Is the growth repeatable?
Is it defensible?
Does it rely on systems or heroes?
Does it clarify the story or complicate it?
Dashboard mockup
The Exit Readiness Signal Framework focuses on the signals that answer those questions.

We’ve seen strong companies lose leverage in diligence not because they lacked growth, but because the growth sent the wrong signals.

The 5 Exit Readiness Signals

NARRATIVE SIGNAL:

Can the growth story be explained clearly and consistently?

Buyers look for a tight narrative that aligns:
  • What the company says it does
  • How it actually makes money
  • Why customers choose it
  • Why that advantage will still matter post‑transaction
Red Flags:
  • Multiple competing stories depending on the audience
  • Growth that’s hard to explain without heavy context
  • New initiatives that don’t clearly ladder to the core thesis
Positive Signal:
A simple, repeatable story that works for customers, partners, and investors alike.

GROWTH QUALITY SIGNAL:

Is growth durable or artificially propped up?

Buyers care less about spikes and more about shape:
  • Mix of new vs. retained revenue
  • Concentration risk
  • Dependency on discounts, promotions, or manual effort
Red Flags:
  • Growth driven by one channel, one partner, or one personality
  • Heavy customization that doesn’t scale
  • Revenue that increases effort faster than margins
Positive Signal:
Growth that improves margin, predictability, and confidence.

OPERATIONAL SIGNAL:

Does growth reduce friction or add complexity?

Every growth investment either:
  • simplifies the business, or
  • makes it harder to run and explain
Red Flags:
  • New products, services, or spin‑outs without clear operational boundaries
  • Workarounds replacing systems
  • Teams that can’t articulate how things actually flow
Positive Signal:
Operations that look intentional, documented, and transferable.

LEADERSHIP SIGNAL:

Can the business run without the founder in every decision?

Buyers underwrite teams as much as numbers especially in founder-led companies.
Red Flags:
  • Founder‑dependent sales or partnerships
  • Decision‑making bottlenecks
  • Strategy living in people’s heads, not in systems
Positive Signal:
Clear ownership, strong second‑layer leadership, and repeatable decision frameworks.

CAPITAL DISCIPLINE SIGNAL:

Are you investing in value creation or value distraction?

Not all growth spend is equal in diligence. Buyers don’t just underwrite ROI. They underwrite whether capital choices made the business easier or harder to own.
Red Flags:
  • Over‑investing in assets buyers discount or strip out
  • Launching initiatives too early in the exit cycle
  • Building things a buyer would prefer to build themselves
Positive Signal:
Capital deployed in ways that increase optionality and reduce the buyer's risk.

HOW TO USE THIS FRAMEWORK

This framework is designed to be used as a pause button before momentum turns into a mess.
It is most powerful when applied:
Before green‑lighting major growth initiatives
Before launching a new product, vertical, or spin‑out
Before adding significant headcount or fixed cost
Before telling a new story to the market
Ask one simple question:
Does this decision strengthen or weaken our Exit Readiness Signals?

If the answer is unclear, that’s the signal.
Dashboard mockup
The outcome
Teams that use this framework consistently:
Grow with intention, not momentum alone
Enter diligence with fewer surprises
Defend valuation with confidence
Preserve strategic options for exits, recaps, or NewCo launches
Exit readiness isn’t a phase. It’s a way of making decisions.
The question most teams miss is whether their current growth choices are strengthening or weakening that posture. This framework reflects how buyers actually evaluate growth in healthcare, pharmacy, and health-tech companies.

About Legacy DNA

Legacy DNA is a growth partner for mid-market healthcare companies, built to maximize your valuation and exit outcomes. Our senior, coordinated team delivers results under pressure, with four successful exits under our belt.

We work exclusively with PE-backed and mid-market healthtech and pharmacy leaders who need faster traction, stronger positioning, and growth that holds up under buyer scrutiny. Our work is senior-led, framework-driven, and built to perform where it matters most: in boardrooms, IC meetings, and diligence conversations.

The Exit Readiness Sprint™
The Exit Readiness Sprint is a 90-day engagement that helps leadership teams make the value they've built obvious to the people who decide what it's worth. We close the gap between what your business is and what buyers, investors, and partners immediately understand it to be.

You leave with a clear, aligned growth story, plus the tools your team, your board, and your buyers can rely on.
Learn more →

THE SIGNALS BUYERS CARE ABOUT ARE FORMING THEIR OPINION RIGHT NOW.

Not at LOI. Not at diligence. Now. In every conversation, every investor update, and every partnership discussion where someone is quietly asking: Does this story hold up?

Most teams discover the gaps too late to fix them cleanly.

If one or more of these signals gave you pause, that pause is worth paying attention to.

Your Next Step

Schedule Your
Strategic Fit Call

It’s a practical conversation to determine whether the Enterprise Value Creation System™ fits your situation and what will most effectively strengthen your valuation.

No pitch. No pressure. Just clarity.

Book my Strategic Fit Call ->